BAR Reddit Mentions | ChartExchange

Hey, this is Emre. I'm building a small tool (catalystintel.io). Before a biotech readout comes out, it writes down what the data has to show and locks that checklist. After the press release, it grades the release against the checklist line by line.
>Normally subscriber-only at first. This one's public so you can see how it works. Grade coming in this thread.
Full event page, public with no signup, including every source document: [https://catalystintel.io/events/IVVD-VYD2311-2026](https://catalystintel.io/events/IVVD-VYD2311-2026)
**What happened today**
Invivyd reported LIBERTY, the Phase 3 safety study of VYD2311 vs Comirnaty in 210 healthy adults aged 18-49. In the first 6 days, 56.5% of people on VYD2311 had an adverse event, injection site reaction or hypersensitivity reaction, vs 91.4% on the vaccine (p<0.0001). I think that's a clean result on the question the study asked.
The part I think matters more is further down the same release. DECLARATION is the \~2,400 person placebo-controlled trial, with a single-dose arm and a monthly-dose arm. It's the trial with the efficacy endpoint (PCR-confirmed symptomatic COVID). The company says the clinical events collected so far will stay blinded. What we get in October is placebo-controlled safety, neutralizing antibody titers and PK. They plan to file for accelerated approval on that, and DECLARATION continues as the confirmatory trial targeting a 70-90% relative risk reduction.
So to be honest, the October data can't answer "does it prevent COVID". What it can answer is whether titers and PK land where the company needs them to, and whether placebo-controlled safety holds up in a big trial.
**The checklist**
Locked 2026-09-30 02:02 UTC, before any DECLARATION data:
EVENT IVVD-VYD2311-2026
SCORED SET ITT
FLOOR safety_grade_floor The readout should not exceed the prior VYD2311-related safety benchmark.
BAR efficacy_target_floor The reported relative risk reduction must reach the lower end of the company's stated target against placebo.
SHA-256: `13f46bbcf995a82f3d6eb21cc6c5c02936aa8734e66f307a9a93ac8564f10b7a`
**What each line means and where it comes from**
Safety floor: the October data shouldn't look worse than the earlier VYD2311 Phase 1/2 study. From the Q4/FY2025 results release: "IM administered VYD2311, at 4 times the planned dose in DECLARATION, was well tolerated, with all adverse events (AEs) considered mild to moderate in severity with no serious or severe AEs reported."
Efficacy bar: at least a 70% relative risk reduction vs placebo. That's the low end of the company's own target, from today's LIBERTY release: "target efficacy (70%-90% relative risk reduction in PCR+ symptomatic COVID-19 versus placebo)". It's not a number I calculated, it's theirs.
Scored set: ITT. No filing says which population they'll report the results in. If they report something narrower, the grade will say so.
Being upfront about the obvious problem: the efficacy line almost certainly can't be graded in October, because the events stay blinded. I'm keeping it anyway. It's the question that decides whether this is a real prevention drug, and I'd rather the grade say "not reported" than quietly drop the line that matters. Titers and PK aren't on the checklist because the company hasn't published a number for what counts as enough, and I didn't want to make one up.
**Three ways October could go**
* **Strong**: efficacy is reported at or above 70% and safety is at or better than the Phase 1/2 benchmark. That would support a traditional BLA. Given today's release, I think this is unlikely to happen in October.
* **Middle**: safety and antiviral activity look good, but the events stay blinded or efficacy doesn't clear 70%. The company would file for accelerated approval and keep collecting events in a confirmatory cohort. Today's release basically describes this case.
* **Weak**: no convincing placebo-controlled prevention effect, or safety comes in materially worse than the benchmark. No filing states a formal failure rule, so I can't say more precisely what that would mean for the filing.
**Regulatory context worth knowing**
In August 2025 Invivyd said the FDA advised a traditional BLA pathway with "a primary endpoint of RT-PCR-confirmed symptomatic COVID-19", measured at around 12 weeks, with a possible 24-week timepoint. The accelerated approval route on titers is a different path from the one that advice described.
The company also points to pemivibart's CANOPY trial as context. It's a related antibody from the same lineage but a different molecule, so I didn't use it for anything on the checklist.
**What I couldn't find in any filing**
* no ClinicalTrials.gov record matching DECLARATION, so there's no registered primary outcome to copy
* no stated analysis population (ITT, mITT etc)
* no public success margin, alpha or event-count trigger for efficacy
* no public number for what titer level would count as enough
* no exact date, just "October"
* enrollment grew across filings from 1,770 planned to \~2,301 to \~2,400 as the trial was upsized
**Sources**
The checklist is built from 11 company documents pulled from EDGAR. Stored copies of all of them are on the event page, so you can check exactly what was read:
* LIBERTY topline results release (Sep 29, 2026)
* Q2 2026 10-Q, liquidity section
* Q1 2026 financial results release
* Q1 2026 earnings call deck (May 14, 2026)
* CEO appointment release (Marc Elia), with the DECLARATION and LIBERTY timing update
* January 2026 corporate deck
* Q4 and full-year 2025 results release, with the DECLARATION trial update
* Q3 2025 financial results release
* August 2025 corporate deck
* FDA alignment on the BLA pathway release (Aug 14, 2025)
* Phase 1 first-dosing release (Sep 4, 2024)
The tool is watching for the release through October 31. When it lands, it scores the release against these two lines, I review the result, and I'll post it here.
This isn't a trade idea and I'm not calling it bullish or bearish, it's just what the bar is. If I got anything wrong above please tell me, I'd rather fix it now than after the data.
Not financial advice.